Zheng J, Zhu Y, Sun K, et al. - In patients who have non-small cell lung cancer (NSCLC) with genomic rearrangement between echinoderm microtubule-associated protein-like 4 ( EML4) and anaplastic lymphoma kinase ( ALK) crizotinib is an effective therapy, but clinical results vary among these patients, so researchers assessed concurrent molecular factors that may influence clinical results to crizotinib therapy in these patients. From 32 crizotinib-managed patients with EML4-ALK-rearranged advanced NSCLC, they retrospectively assessed data. They found that patients with concurrent deleterious mutations, especially copy number amplifications, had significantly decreased progression-free survival, vs those without these mutations. Shorter progression-free survival was reported in correlation with having more copy number variations. Overall, findings are indicative of the prognostic implications of concurrent deleterious mutations, especially copy number amplifications in oncogenic genes, in patients with EML4-ALK-rearranged NSCLC on crizotinib therapy.